Back to Newsroom
Back to Newsroom

Five Star Equities Issues New Research Reports on DWCH, ISR, MGNX and RGDO

Monday, 14 April 2014 08:40 AM

Topic:

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Datawatch Corporation (NASDAQ: DWCH) shares tumbled 29.16 percent to close at $14.67 a share Friday. The stock traded between $13.30 and $15.32 on volume 2.43 million shares traded. The company announced that it expects revenues for the second quarter of fiscal 2014 to be between $7.8 and $8.0 million, which was below the average analyst forecast of $8.61 million. Shares of Datawatch are down approximately 57.0 percent year-to-date.

Get more information on Datawatch and free access to the in-depth equity report at:  
www.FiveStarEquities.com/DWCH

IsoRay, Inc. (NYSEMKT: ISR) shares increased 5.26 percent to close at $2.80 a share Friday. The stock traded between $2.48 and $2.85 on volume of 7.10 million shares traded. The company recently announced the first prostate cancer implant combining IsoRay's Cesium-131 seeds with C4 Imaging's Sirius positive signal MRI markers.

Get more information on IsoRay and free access to the in-depth equity report at:  
www.FiveStarEquities.com/ISR

MacroGenics Inc. (NASDAQ: MGNX) shares fell 13.24 percent to close at $20.38 a share Friday. The stock traded between $19.95 and $23.49 on volume of 662,536 shares traded. The company has extended its collaboration with MacroGenics Inc. to produce novel antibody drug conjugates. Shares of MacroGenics are down approximately 25.0 percent year-to-date.

Get more information on MacroGenics and free access to the in-depth equity report at:  
www.FiveStarEquities.com/MGNX

Regado Biosciences Inc. (NASDAQ: RGDO) shares dropped 18.41 percent to close at $5.85 a share Friday. The stock traded between $5.69 and $6.11 on volume 4.41 million shares traded. The company announced the pricing of a public offering of 10.0 million shares of common stock at a price of $16.00 per share to the public. Shares of Regado Biosciences are up approximately 22.0 percent year-to-date.

Get more information on Regado Biosciences free access to the in-depth equity report at:  
www.FiveStarEquities.com/RGDO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:          
Five Star Equities
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: